Valuation: Qiagen N.V.

Capitalization 6.82B 5.87B 5.37B 5.12B 9.39B 654B 9.54B 64.38B 24.91B 311B 25.6B 25.05B 1,082B P/E ratio 2026 *
15.7x
P/E ratio 2027 * 15.1x
Enterprise value 7.35B 6.32B 5.78B 5.51B 10.11B 705B 10.28B 69.34B 26.83B 335B 27.57B 26.98B 1,166B EV / Sales 2026 *
3.41x
EV / Sales 2027 * 3.18x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * 0.57%
1 day-0.93%
1 week-0.18%
Current month-4.63%
1 month-20.03%
3 months-32.36%
6 months-29.00%
Current year-30.33%
1 week 32.53
Extreme 32.53
33.98
1 month 32.53
Extreme 32.53
41.56
Current year 32.53
Extreme 32.53
57.82
1 year 32.53
Extreme 32.53
57.82
3 years 32.53
Extreme 32.53
57.82
5 years 32.53
Extreme 32.53
64.74
10 years 23.11
Extreme 23.113
65.86
Manager TitleAgeSince
Chief Executive Officer 61 06/10/2019
Director of Finance/CFO 58 31/12/2003
Chief Operating Officer - 31/03/2022
Director TitleAgeSince
Director/Board Member 71 31/12/2003
Director/Board Member 77 31/05/2011
Director/Board Member 60 07/01/2021
Change 5d. change 1-year change 3-years change Capi.($)
-0.93%-0.18%-26.54%-34.27% 6.82B
-1.01%-2.82%-18.17%-17.01% 41.67B
-3.73%-6.04%+28.41%+26.96% 32.6B
-2.55%+2.71%+268.39%+461.74% 30.97B
-0.91%-5.37%+18.41%-12.40% 28.23B
-3.23%-4.84%+27.50%+22.65% 26.41B
-2.03%+0.77% - - 14.94B
+6.21%-2.39%+176.35%+4,385.95% 14.13B
-1.92%-1.95%+121.19%+104.49% 12.27B
-0.20%-0.10%+5.63%-0.70% 12.12B
Average -1.03%-1.67%+66.80%+548.60% 22.02B
Weighted average by Cap. -1.49%-2.11%+66.24%+378.82%

Financials

2026 *2027 *
Net sales 2.15B 1.85B 1.7B 1.62B 2.97B 207B 3.01B 20.34B 7.87B 98.15B 8.09B 7.91B 342B 2.27B 1.95B 1.79B 1.71B 3.13B 218B 3.18B 21.44B 8.3B 103B 8.52B 8.34B 360B
Net income 406M 349M 319M 304M 558M 38.91B 567M 3.83B 1.48B 18.47B 1.52B 1.49B 64.35B 467M 402M 367M 350M 642M 44.78B 653M 4.41B 1.7B 21.26B 1.75B 1.71B 74.06B
Net Debt 526M 453M 414M 395M 724M 50.47B 736M 4.97B 1.92B 23.96B 1.97B 1.93B 83.47B 406M 349M 319M 304M 558M 38.91B 567M 3.83B 1.48B 18.47B 1.52B 1.49B 64.35B
Logo Qiagen N.V.
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Employees
5,500
Date Price Change Volume
15/05/26 32.98 $ -0.93% 1,803,429
14/05/26 33.29 $ +1.80% 3,312,819
13/05/26 32.70 $ -2.97% 4,032,489
12/05/26 33.70 $ +3.28% 3,286,268
11/05/26 32.63 $ -1.24% 1,832,641
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
32.98USD
Average target price
43.82USD
Spread / Average Target
+32.87%

Quarterly revenue - Rate of surprise